HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Oncology1 paper

Metastatic amelanotic malignant melanoma to skin

Last edited: 4/10/2026

Overview

Amelanotic melanoma is a variant of malignant melanoma that lacks melanin pigment, making it more challenging to diagnose clinically. Metastatic amelanotic melanoma signifies the spread of this cancer to distant sites, including the skin.

Diagnosis

  • Clinical diagnosis can be difficult due to the absence of typical pigmented lesions 1.
  • Biopsy with histopathological examination is essential for definitive diagnosis 1.
  • Staging workup typically includes imaging studies to assess for distant metastases 1.

    • Management

  • Treatment strategies for metastatic amelanotic melanoma are similar to those for metastatic pigmented melanoma and depend on the extent of disease and patient factors 1.
  • Systemic therapies, including immunotherapy (e.g., checkpoint inhibitors) and targeted therapy (if BRAF or MEK mutations are present), are mainstays of treatment 1.
  • Surgical resection may be considered for isolated metastases 1.

    • Key Recommendations

  • Definitive diagnosis of amelanotic melanoma requires histopathological examination of a biopsy specimen 1. (Evidence: Strong)
  • Treatment for metastatic amelanotic melanoma should be guided by staging and patient characteristics, often involving systemic therapies like immunotherapy or targeted therapy 1. (Evidence: Moderate)
  • Clinical suspicion for amelanotic melanoma should be high in non-pigmented or atypical skin lesions, prompting prompt biopsy 1. (Evidence: Expert opinion)

    • References

    1 Dupuis MM. Tamales. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025. link

    Original source

    1. [1]
      Tamales. — Dupuis MM Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG